Mar 30, 2020
Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC(TM), Dosed Every Other Day, for the Preventive Treatment of Migraine
Jan 31, 2020
Lilly's REYVOW(TM) (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription
Dec 23, 2019
Allergan Receives U.S. FDA Approval for UBRELVY(TM) for the Acute Treatment of Migraine with or without Aura in Adults
Dec 23, 2019
FDA approves new treatment for adults with migraine
Dec 17, 2019
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
Dec 04, 2019
Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine
Nov 29, 2019
World Migraine Therapeutics Market Study 2019-2024 - Triptans Projected to Grow at a Healthy CAGR
Jul 11, 2019
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Jun 24, 2019
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
Dec 10, 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Oct 17, 2018
Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Jun 28, 2018
Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig(TM) (erenumab-aooe) In Patients With Chronic And Episodic Migraine
Jun 28, 2018
Allergan's Study in Chronic Migraine Receives Migraine Research Award at the American Headache Society's 60th Annual Scientific Meeting
Jun 28, 2018
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Jun 27, 2018
Promius Pharma Announces Migraine Presentations at the 60th Annual Scientific Meeting of the American Headache Society
Jun 11, 2018
Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial
May 17, 2018
FDA approves novel preventive treatment for migraine
Apr 27, 2018
Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant -- an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Feb 06, 2018
Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Nov 27, 2017
Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant